ProfileGDS5672 / 1557267_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
OrganismHomo sapiens


control bevacizumab dibenzazepine GSM958322 GSM958323 GSM958324 GSM958328 GSM958329 GSM958330 GSM958325 GSM958326 GSM958327 67% 67% 69% 69% 69% 71% 72% 71% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM958322U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2]5.7803767
GSM958323U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2]5.7031867
GSM958324U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2]6.0824969
GSM958328U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2]6.2476369
GSM958329U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2]6.2406669
GSM958330U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2]6.5049471
GSM958325U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2]6.7382772
GSM958326U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2]6.6834871
GSM958327U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2]6.147469